Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis-Reference-Cited by-同舟云学术

Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis

Published:2018-04 Issue:4 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Britt Nicholas S.¹,Ritchie David J.¹²,Kollef Marin H.³,Burnham Carey-Ann D.⁴⁵⁶,Durkin Michael J.⁷,Hampton Nicholas B.⁸,Micek Scott T.¹²

Affiliation:

1. Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA

2. Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, USA

3. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

4. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

5. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA

6. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA

7. Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

8. Center for Clinical Excellence, BJC HealthCare, St. Louis, Missouri, USA

Abstract

ABSTRACT In a retrospective analysis of 215 patients with carbapenem-resistant Pseudomonas aeruginosa sepsis, we observed a significantly higher risk of mortality associated with respiratory tract infection (risk ratio [RR], 1.20; 95% confidence interval [CI], 1.04 to 1.39; P = 0.010) and lower risk with urinary tract infection (RR, 0.80; 95% CI, 0.71 to 0.90; P = 0.004). Aminoglycoside monotherapy was associated with increased mortality, even after adjusting for confounders (adjusted RR, 1.72; 95% CI, 1.03 to 2.85; P = 0.037), consistent across multiple sites of infection.

Funder

HHS | National Institutes of Health

Foundation for Barnes-Jewish Hospital

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02400-17

Reference11 articles.

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.

2. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

3. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014

4. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis

5. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacteriophage Therapy to Combat ESKAPE Pathogens;ESKAPE Pathogens;2024

2. Carbapenem is not always the best choice in the treatment of septic shock;European Journal of Medical Research;2023-09-25

3. Advancement of Phage Therapy Approaches in The Battle of Multi-Drug Resistance: A Review;International Journal of Life Science and Pharma Research;2023-03-01

4. Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis;Antibiotics;2022-10-18

5. The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections;Infection and Drug Resistance;2022-06